A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Clinical trial NCT01722331 · COMPLETED

Trial details

NCT number: NCT01722331
Sponsor: Sun Pharmaceutical Industries Limited
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2012-12-06
Primary completion: 2015-10-28
Enrollment: 772

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.